Amphastar Pharmaceuticals AMPH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Geography | |||||
| CN | $3.18M-26.6% | $4.34M-3.7% | $4.51M-4.1% | $4.7M-22.0% | |
| FR | $35.28M+76.9% | $19.95M+325% | $4.7M-37.0% | $7.46M-37.2% | |
| US | $681.42M-3.7% | $707.68M+11.4% | $635.19M+30.5% | $486.83M+15.9% | |
| Non-Current Assets by Geography | |||||
| CN | $440.58M+10.0% | $400.49M+11.2% | $360.06M+0.7% | $357.47M-4.8% | |
| FR | $146.14M+1.5% | $143.99M-6.0% | $153.19M-3.5% | $158.82M-16.5% | |
| US | $829.02M-56.6% | $1.91B+2.1% | $1.87B+243% | $544.18M+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amphastar Pharmaceuticals break its business down?
- Amphastar Pharmaceuticals (AMPH) reports revenue by business across 2 parts — Finished Pharmaceutical Products and Pharmaceutical Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Amphastar Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amphastar Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
